Comparisons

Saxenda vs Wegovy: Effectiveness and Side Effect Comparison

GLP-1 Companion · 8 min read

Saxenda (liraglutide 3.0 mg) and Wegovy (semaglutide 2.4 mg) are both manufactured by Novo Nordisk and both act on GLP-1 receptors to produce weight loss. Despite their shared drug class and manufacturer, they are meaningfully different medications in terms of molecular structure, dosing schedule, efficacy, and cost. Understanding those differences is essential for patients and clinicians choosing between them.

Quick Facts: Saxenda vs Wegovy

• Active ingredient: Saxenda contains liraglutide; Wegovy contains semaglutide
• Dosing frequency: Saxenda is injected once daily; Wegovy is injected once weekly
• Maintenance dose: Saxenda 3.0 mg/day; Wegovy 2.4 mg/week
• FDA approval year for obesity: Saxenda 2014; Wegovy 2021
• Manufacturer: Both are made by Novo Nordisk
• Generic availability: Generic liraglutide (Saxenda equivalent) approved August 2025; no generic Wegovy as of April 2026

Mechanism of Action: How They Differ Molecularly

Both drugs are GLP-1 receptor agonists, but they are structurally distinct molecules. Liraglutide has 97% homology to human GLP-1 and is bound to a fatty acid chain that allows it to self-associate and bind albumin in the bloodstream, extending its half-life to approximately 13 hours — enough for once-daily dosing. Semaglutide has a different fatty acid attachment and a modified peptide backbone that resists enzymatic degradation more effectively, extending its half-life to approximately 7 days and enabling once-weekly dosing. Both drugs suppress appetite primarily through hypothalamic and brainstem GLP-1 receptors, but semaglutide's longer receptor engagement may contribute to its greater efficacy.

Weight Loss Results: A Clear Efficacy Gap

The efficacy difference between Saxenda and Wegovy is substantial and has been consistently demonstrated across clinical trial programs.

• Saxenda (SCALE trials): Average weight loss of 5 to 8 percent of body weight over 56 weeks in patients without diabetes
• Wegovy (STEP 1 trial): Average weight loss of 14.9 percent of body weight over 68 weeks in patients without diabetes
• At least 5% weight loss: ~63% of Saxenda patients vs ~86% of Wegovy patients
• At least 10% weight loss: ~33% of Saxenda patients vs ~70% of Wegovy patients
• At least 15% weight loss: ~16% of Saxenda patients vs ~51% of Wegovy patients

For a person weighing 250 pounds, this difference translates to approximately 12 to 20 pounds lost on Saxenda versus approximately 35 to 40 pounds on Wegovy. Both are clinically significant, but the difference is hard to ignore for patients whose primary goal is maximum weight reduction.

Side Effect Comparison

Both medications share a similar side effect profile because they act on the same receptor family. Gastrointestinal symptoms dominate.

• Nausea: ~39% with Saxenda vs ~44% with Wegovy during escalation
• Diarrhea: ~21% with Saxenda vs ~30% with Wegovy
• Vomiting: ~15% with Saxenda vs ~24% with Wegovy
• Constipation: ~19% with Saxenda vs ~24% with Wegovy
• Discontinuation due to GI side effects: ~9-10% with Saxenda vs ~7% with Wegovy (STEP 1)

Wegovy's slower escalation schedule — reaching the 2.4 mg maintenance dose over 16 weeks compared to Saxenda's 5-week escalation — may help explain why its clinical trial discontinuation rates were not substantially higher despite greater efficacy. Some patients find the once-weekly rhythm of Wegovy easier to manage than the daily injection burden of Saxenda.

Shared Serious Risks

• Both carry a black-box warning for thyroid C-cell tumor risk based on rodent studies
• Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2
• Both increase the risk of pancreatitis and gallbladder disease
• Both can cause injection site reactions and increased resting heart rate

Dosing Frequency and Administration

This is one of the most practical differences between the two medications. Saxenda requires a daily injection, meaning approximately 365 injections per year. Wegovy requires only 52 injections per year. For many patients, adherence is meaningfully better with weekly dosing because it integrates more easily into a routine and produces less injection site fatigue. Studies on GLP-1 adherence in real-world settings consistently show higher persistence with once-weekly formulations.

Cost and Insurance Coverage

Cost is where Saxenda's competitive position has significantly improved since 2025.

• Brand Saxenda list price: approximately $1,350 to $1,450 per month
• Generic liraglutide 3.0 mg (as of late 2025): approximately $300 to $500 per month
• Wegovy list price: approximately $1,350 per month; no generic available as of April 2026
• Wegovy manufacturer savings card: reduces out-of-pocket cost to $0 to $25 for eligible commercially insured patients
• Medicaid coverage: Several state Medicaid programs cover liraglutide but not semaglutide for obesity; check your specific state formulary

For patients who are uninsured or underinsured and do not qualify for the Wegovy savings program, generic liraglutide now offers a substantially more affordable path to GLP-1 therapy for weight management. For patients with commercial insurance and manufacturer savings card access, the monthly out-of-pocket difference may be negligible.

Cardiovascular Outcomes

Liraglutide (at the 1.8 mg diabetes dose) demonstrated cardiovascular benefit in the LEADER trial, reducing major adverse cardiovascular events in patients with type 2 diabetes. Semaglutide demonstrated cardiovascular benefits in SUSTAIN-6 (diabetes) and more dramatically in the SELECT trial (2023), which showed a 20% reduction in cardiovascular events in patients with obesity but without diabetes on semaglutide 2.4 mg. The SELECT finding is particularly relevant for Wegovy patients who choose it primarily for weight management, as it provides additional clinical justification. No equivalent SELECT-style trial has been completed for liraglutide 3.0 mg.

Who Might Still Choose Saxenda (or Generic Liraglutide)?

• Patients on Medicaid plans that cover liraglutide but not semaglutide for obesity
• Cost-sensitive patients without commercial insurance or savings card eligibility
• Adolescents aged 12 to 17 (Saxenda is FDA-approved for this age group; Wegovy was approved for adolescents 12+ in 2022 as well, but access varies)
• Patients who have already lost meaningful weight on Saxenda and wish to continue
• Patients who experienced fewer side effects on daily liraglutide than on weekly semaglutide

Head-to-Head Summary

• Efficacy: Wegovy wins clearly (~15-17% vs ~5-8% weight loss)
• Dosing convenience: Wegovy wins (weekly vs daily)
• Cost without insurance: Generic liraglutide wins as of 2025-2026
• GI side effect burden: Roughly comparable; Wegovy slightly higher rates but similar discontinuation
• Cardiovascular evidence: Wegovy has stronger obesity-specific CV outcome data (SELECT trial)
• Formulary access for Medicaid: Liraglutide may have an edge in certain states

For most new patients starting GLP-1 therapy for obesity in 2026, Wegovy or a tirzepatide-based product will be the clinical preference if insurance coverage is available. Generic liraglutide fills an important role for those facing cost or formulary barriers.

The Bottom Line

Saxenda and Wegovy work through similar mechanisms but produce meaningfully different weight loss outcomes. Wegovy is the stronger medication in terms of both efficacy and cardiovascular evidence. However, the 2025 approval of generic liraglutide has given Saxenda renewed relevance for patients who need a lower-cost option or whose insurance favors it. The right choice depends on your individual medical profile, insurance, and treatment goals — a conversation best had with your prescribing clinician.

Sources

• Saxenda (liraglutide 3.0 mg) Prescribing Information. Novo Nordisk.
• Pi-Sunyer et al. (2015). Liraglutide 3.0 mg in Weight Management. NEJM.